# A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors

> **NCT05457517** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 49 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** YL-13027，Sintilimab

## Key facts

- **NCT ID:** NCT05457517
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-24
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05457517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05457517, "A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05457517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*